Role of EMP2 in RPE Homeostasis
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2004 - March 31, 2006
Grant ID
M2004028
Summary
Complex interactions between a key cell type, the retinal pigment epithelium (RPE), and the underlying extracellular matrix may play a critical role in the pathophysiology of age-related macular degeneration (AMD) as well as in proliferative vitreoretinopathy (PVR). Dr. Gordon has observed that RPE expresses epithelial membrane protein (EMP2), a protein that may play a significant role in the recruitment and targeted cell surface delivery of certain proteins to specific regions of the cell membrane. The purpose of this study is to test whether the modulation of EMP2 expression in the RPE produces the predicted biological consequences, including altered growth characteristics and changes in patterns of cellular adhesion and migration. The expected improvement in the understanding of the biochemical pathways and the regulation of the various functions performed by the RPE could yield important insight into the pathophysiology of age-related macular degeneration, PVR, and hereditary retinal degeneration. It could also lead to the identification of new targets for the treatment of RPE-associated pathology.
Grants
Related Grants
Macular Degeneration Research
Investigating AMD-Like Disease in Animal Models
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Brittany Carr, PhD
Investigating AMD-Like Disease in Animal Models
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Brittany Carr, PhD
Macular Degeneration Research
The Generation of Cone Photoreceptor Outer Segments
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Heike Kroeger, PhD
The Generation of Cone Photoreceptor Outer Segments
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Heike Kroeger, PhD
Macular Degeneration Research
Innovative Night Vision Tests for Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Maximilian Pfau, MD
Innovative Night Vision Tests for Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2027

Principal Investigator
Maximilian Pfau, MD